ECSP056145A - Beta-carbolinas utiles para tratar enfermedades inflamatorias - Google Patents

Beta-carbolinas utiles para tratar enfermedades inflamatorias

Info

Publication number
ECSP056145A
ECSP056145A EC2005006145A ECSP056145A ECSP056145A EC SP056145 A ECSP056145 A EC SP056145A EC 2005006145 A EC2005006145 A EC 2005006145A EC SP056145 A ECSP056145 A EC SP056145A EC SP056145 A ECSP056145 A EC SP056145A
Authority
EC
Ecuador
Prior art keywords
useful
inflammatory diseases
beta
carbolins
treat inflammatory
Prior art date
Application number
EC2005006145A
Other languages
English (en)
Inventor
Michael E Hepperle
Julie Fields Liu
Francois Soucy
Yingchun Ye
Robert S Murray
Raman Prakash
Jeremy D Little
Alfredo Castro
Hormoz Mazdiyasni
Paul E Fleming
Dominic Reynolds
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of ECSP056145A publication Critical patent/ECSP056145A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta invención proporciona compuestos beta-carbolina de fórmula I: Idonde el Anillo A es un anillo piridinilo, pirimidinilo, morfolinilo, piperidinilo, piperazinilo, pirrolidinilo, piranilo, tetrahidrofuranoilo, ciclohexilo, ciclopentilo o tiomorfolinilo sustituido y R1, R2 y R3 son como se han definido en la memoria descriptiva. Los compuestos son inhibidores de IKK-2 que son útiles para tratar enfermedades mediadas por IKK-2 tales como enfermedades inflamatorias y cáncer.
EC2005006145A 2003-04-09 2005-11-07 Beta-carbolinas utiles para tratar enfermedades inflamatorias ECSP056145A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46146803P 2003-04-09 2003-04-09

Publications (1)

Publication Number Publication Date
ECSP056145A true ECSP056145A (es) 2006-04-19

Family

ID=33299818

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006145A ECSP056145A (es) 2003-04-09 2005-11-07 Beta-carbolinas utiles para tratar enfermedades inflamatorias

Country Status (22)

Country Link
US (2) US7727985B2 (es)
EP (1) EP1611134A1 (es)
JP (1) JP2006522824A (es)
KR (1) KR20060006031A (es)
CN (1) CN1802375A (es)
AU (1) AU2004230952A1 (es)
BR (1) BRPI0409263A (es)
CA (1) CA2521300A1 (es)
CO (1) CO5700746A2 (es)
CR (1) CR8042A (es)
EA (1) EA009121B1 (es)
EC (1) ECSP056145A (es)
HR (1) HRP20050926A2 (es)
MA (1) MA27837A1 (es)
MX (1) MXPA05010793A (es)
NI (1) NI200500174A (es)
NO (1) NO20054598L (es)
OA (1) OA13115A (es)
RS (1) RS20050832A (es)
TN (1) TNSN05257A1 (es)
WO (1) WO2004092167A1 (es)
ZA (1) ZA200508198B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20050832A (sr) 2003-04-09 2007-12-31 Millennium Pharmaceuticals Inc., Beta-karbolini koji su korisni u tretiranju inflamatornih bolesti
DE602005020263D1 (de) * 2004-04-09 2010-05-12 Millennium Pharm Inc Für die behandlung von entzündlichen krankheiten nützliche beta-carboline
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8518964B2 (en) 2005-11-22 2013-08-27 Merck Sharp & Dohme Corp. Tricyclic compounds useful as inhibitors of kinases
CA2646316C (en) 2006-03-15 2016-05-24 Theralogics, Inc. Methods of treating muscular wasting diseases using nf-kb activation inhibitors
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
US20100098641A1 (en) * 2006-12-13 2010-04-22 William Baker Monophosphates as Mutual Prodrugs of Anti-Inflammatory Signal Transduction Modulators (AISTM's) and Beta-Agonists for the Treatment of Pulmonary Inflammation and Bronchoconstriction
WO2009054970A1 (en) * 2007-10-23 2009-04-30 Millennium Pharmaceuticals, Inc. Mesylate salt of an ikk inhibitor
WO2009054965A1 (en) * 2007-10-23 2009-04-30 Millennium Pharmaceuticals, Inc. Salts of n- (6-chloro-9h-pyrido [3,4-b] ind0l-8-yl) -4- [2- (2, 6-dimethyl-4-morpholinyl) -2-0x0e thyl] -6, 6-dimethyl-morpholinecarboxamide
JP5892791B2 (ja) 2008-05-14 2016-03-23 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 適応免疫における免疫調節物質の効果をモニターするための方法およびキット
CN102171204B (zh) 2008-10-02 2014-08-20 旭化成制药株式会社 8位取代异喹啉衍生物及其用途
BR112012024585A2 (pt) 2010-03-30 2016-05-31 Novartis Ag inibidores de pkc para o tratamento de linfomade células b tendo sinalização do receptor de células b ativas crônicas
PL2691394T3 (pl) * 2011-03-28 2017-10-31 Sjt Molecular Res S L Związki do leczenia zespołu metabolicznego
CN102416014B (zh) * 2011-09-13 2012-11-21 河南中医学院 一种生物碱类成分组合物在制备抗甲型h1n1流感病毒药物中的应用
CN102391323B (zh) * 2011-10-18 2013-09-25 首都医科大学 四氢-β-咔啉衍生物、其制备方法及其用途
KR101646916B1 (ko) 2015-07-13 2016-08-09 강원대학교산학협력단 베타-카르볼린 알칼로이드 화합물을 함유하는 염증성 질환의 예방 또는 치료용 조성물
WO2017067670A1 (en) 2015-10-23 2017-04-27 Pharmathen S.A. A novel process for the preparation of tryptamines and derivatives thereof
CN109593089B (zh) * 2019-01-24 2022-01-28 西南大学 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用
CN112824387B (zh) * 2019-11-21 2023-03-21 济南尚博生物科技有限公司 一种2-甲基烟酸酯及其制备方法和应用
CN117510494B (zh) * 2023-11-07 2024-04-19 桂林医学院附属医院 β-咔啉-沙利度胺偶联物及其在制备逆转ABT-199耐药的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4925099A (en) * 1998-08-12 2000-03-06 Pfizer Products Inc. Tace inhibitors
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
EP1268477B1 (en) * 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
KR100826817B1 (ko) * 2000-03-15 2008-05-02 사노피-아벤티스 도이칠란트 게엠베하 치환된 베타-카볼린
ES2286275T3 (es) 2001-09-19 2007-12-01 Pharmacia Corporation Compuestos de pirazolo sustituidos para el tratamiento de la inflamacion.
WO2003039545A2 (en) 2001-11-07 2003-05-15 Millennium Pharmaceuticals, Inc. Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
CN1753884A (zh) * 2003-03-07 2006-03-29 伊莱利利公司 阿片类受体拮抗剂
RS20050832A (sr) 2003-04-09 2007-12-31 Millennium Pharmaceuticals Inc., Beta-karbolini koji su korisni u tretiranju inflamatornih bolesti

Also Published As

Publication number Publication date
NI200500174A (es) 2006-04-17
EP1611134A1 (en) 2006-01-04
CR8042A (es) 2006-05-30
CO5700746A2 (es) 2006-11-30
BRPI0409263A (pt) 2006-03-28
NO20054598D0 (no) 2005-10-06
AU2004230952A1 (en) 2004-10-28
OA13115A (en) 2006-11-10
ZA200508198B (en) 2007-01-31
WO2004092167A8 (en) 2006-01-05
JP2006522824A (ja) 2006-10-05
KR20060006031A (ko) 2006-01-18
CN1802375A (zh) 2006-07-12
US7727985B2 (en) 2010-06-01
US20100093713A1 (en) 2010-04-15
US20040235839A1 (en) 2004-11-25
MA27837A1 (fr) 2006-04-03
RS20050832A (sr) 2007-12-31
EA200501584A1 (ru) 2006-06-30
CA2521300A1 (en) 2004-10-28
TNSN05257A1 (en) 2007-07-10
WO2004092167A1 (en) 2004-10-28
NO20054598L (no) 2005-10-27
EA009121B1 (ru) 2007-10-26
HRP20050926A2 (en) 2006-06-30
MXPA05010793A (es) 2005-12-05

Similar Documents

Publication Publication Date Title
ECSP056145A (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
CO6870032A2 (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
MX2022001181A (es) Inhibidores de kif18a.
CY1121651T1 (el) Ετεροκυκλυλαμινες ως αναστολεις ρι3κ
PH12019501350B1 (en) Amino-triazolopyridine compounds and their use in treating cancer
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
CL2022000093A1 (es) Imidazopirimidinas como inhibidores de eed y uso de estas
CU20120101A7 (es) Derivados de triazolopirazinas sustituidas como inhibidores del receptor c-met o hgf para tratar el cáncer
MX2019005232A (es) Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
UY29458A1 (es) Heterociclos sustituidos y usos de los mismos
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
TN2009000389A1 (en) Pyrido [2,3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer
ECSP11010867A (es) Compuestos novedosos de fenilamino-isonicotinamida
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
UY29414A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
EA201170344A1 (ru) Азаиндольные ингибиторы iap
CO2023010694A2 (es) Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
CR8696A (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
ECSP045477A (es) COMPUESTOS DE AMIDAS DE ÁCIDO3-AMINO-TIENO[2,3-b]PIRIDINO-2-CARBOXÍLICO SUSTITUIDOY PROCEDIMIENTOS PARA PREPARARLOS Y SUS USOS.
CR8288A (es) 6-[ (sustituido) fenil] triazolopirimidinas como agentes anticancer
MX2024007863A (es) Uso de compuestos de aminopirazol.
PE20150348A1 (es) Compuestos de azetidina y piperidina utiles como inhibidores de pde10